<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1024">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377711</url>
  </required_header>
  <id_info>
    <org_study_id>ALV-020-001</org_study_id>
    <nct_id>NCT04377711</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Covis Pharma S.à.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Covis Pharma S.à.r.l.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide)
      Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a
      multicenter, randomized, double-blind, placebo controlled study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients hospital admission or death by day 30</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality by day 30</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19-related mortality by day 30</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID 19 by day 30</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital admission or death</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, &gt; 3 AM/PM assessments)</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in oxygen saturation levels</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in COVID-19 viral load in nasopharyngel sample nasal secretions at day 30</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed based on adverse events.</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Alvesco 320mcg, twice daily for 30 days via pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive Placebo matching Alvesco , twice daily for 30 days via pMDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>160mcg Inhaler</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo Inhaler</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients eligible for enrollment in the study must meet all the following criteria:

          1. Male and female adults and adolescents (12 years of age and above).

          2. Positive SARS-CoV-2 rapid molecular diagnostic test within 72 hours prior to
             enrollment.

          3. Patient is not currently hospitalized or under immediate consideration for
             hospitalization at the time of enrollment.

          4. Patient is currently experiencing symptoms of fever, cough, and/or dyspnea.

          5. Patient has an oxygen saturation level greater than 93%.

          6. Ability to show adequate use of MDI, including inhalation technique.

          7. Patient, parent/legal guardian, or legally-authorized representative must have signed
             a written informed consent before administration of any study-specific procedures.

        Exclusion Criteria

        Patients meeting any of the following criteria are not eligible for participation in the
        study:

          1. Existence of any life-threatening co-morbidity or any other medical condition which,
             in the opinion of the investigator, makes the patient unsuitable for inclusion.

          2. History of hypersensitivity to ciclesonide.

          3. Treatment with inhaled or intranasal corticosteroids within 14 days of the screening/
             enrollment/randomization visit.

          4. Treatment with oral corticosteroids within 90 days of the
             screening/enrollment/randomization visit.

          5. Participation in any other clinical trial or use of any investigational agent within
             30 days of the screening/enrollment/randomization visit.

          6. Currently receiving treatment with hydroxychloroquine/chloroquine.

          7. Patients with cystic fibrosis.

          8. Patients with idiopathic pulmonary fibrosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Clemency, MD</last_name>
      <phone>716-604-7554</phone>
      <email>bc34@buffalo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

